StockTipsArenaBeta

BUY Glenmark Pharmaceuticals — Rahul Sharma, JM Financial

BUYGlenmark Pharmaceuticals
Glenmark Pharmaceuticals share price target & all analyst calls

byRahul Sharma, JM FinancialHorizon: 1–3 months29 Jun 2026via CNBC Awaaz.

Entry₹2,180Stated
Target₹2,380
Total upside +9.17% (call closed)
Stop loss₹2,140-1.83% risk
Exit₹2,38024 Aug 2026, 12:08 pm
Target hit+9.17%0.00%upside left
Follow Rahul Sharma for new calls(30% target hit, 33 closed calls)Get alertsWatch GLENMARK for new buy/sell callsGet alertsSee 2 active Short-term calls on GLENMARKSee 43 active Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 24 Aug 2026
15 supporting4 neutral2 opposing
Supports the BUY call (15)

Glenmark Pharmaceuticals Inc., USA has launched a new Calcium Gluconate Injection product in various strengths and vial sizes.

BSE · Company Update·21 Aug · 3d ago

(opens in new tab)

4 advisors have active long-term BUY calls on this stock, with 2 issued in the last 14 days

Advisor consensus · adjacent horizon·21 Aug · 3d ago

Glenmark Pharmaceuticals has received approval from the U.S. FDA for its Fluticasone Propionate Nasal Spray, 0.05 mg (50 mcg)/spray.

BSE · Company Update·20 Aug · 4d ago

(opens in new tab)

2 other SEBI-registered advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · same horizon·20 Aug · 4d ago

Glenmark Pharma Q1 Revenue Beats Estimates, EBITDA Margins Seen Rising

NewsGoogle News·4 Aug · 3w ago

(opens in new tab)
Neutral / worth noting (4)

Glenmark USA has agreed to a settlement of $15.28 million to resolve antitrust and consumer protection lawsuits related to price-fixing allegations. The company denies all allegations and states the s

BSE · Company Update·11 Aug · 2w ago

(opens in new tab)

Glenmark Pharma Q1 FY27 Results and Brokerage Outlook

NewsGoogle News·4 Aug · 3w ago

(opens in new tab)

Glenmark Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

NSE · Outcome of Board Meeting·31 Jul · 3w ago

(opens in new tab)

The Board of Directors has considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026

BSE · Board Meeting·31 Jul · 3w ago

(opens in new tab)
Weighs against the BUY call (2)

Glenmark Pharma US arm agrees to $15.28 million settlement with Humana over antitrust lawsuits

NewsCnbc-Tv18·12 Aug · 2w ago

(opens in new tab)

1 advisor has an active long-term SELL call on this stock

Advisor consensus · adjacent horizon·3 Feb · 7mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Glenmark Pharmaceuticals

All analyst calls on Glenmark Pharmaceuticals

More from Rahul Sharma, JM Financial

Every call and its outcome